Ventyx Biosciences (NASDAQ:VTYX) Given Neutral Rating at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Ventyx Biosciences (NASDAQ:VTYX) in a research note published on Monday,Benzinga reports. HC Wainwright currently has a $6.00 price objective on the stock.

Several other analysts have also weighed in on VTYX. Canaccord Genuity Group reduced their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. Finally, Wells Fargo & Company dropped their price objective on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating for the company in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Ventyx Biosciences Price Performance

NASDAQ VTYX opened at $1.97 on Monday. The business has a fifty day moving average price of $2.24 and a two-hundred day moving average price of $2.79. The stock has a market capitalization of $139.30 million, a PE ratio of -0.85 and a beta of 0.37. Ventyx Biosciences has a fifty-two week low of $1.79 and a fifty-two week high of $11.48.

Institutional Trading of Ventyx Biosciences

Hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its holdings in Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock valued at $30,000 after buying an additional 5,310 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. Norden Group LLC acquired a new position in shares of Ventyx Biosciences during the first quarter worth $59,000. Palumbo Wealth Management LLC bought a new stake in shares of Ventyx Biosciences in the third quarter worth $26,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Ventyx Biosciences in the first quarter valued at $72,000. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.